iBio

iBio is a biopharmaceutical company based in San Diego, CA, United States, focused on developing next-generation antibody therapies for complex diseases. The organization primarily targets obesity, cardiometabolic disorders, and hard-to-target cancers, addressing significant unmet patient needs in these therapeutic areas. iBio leverages an AI-driven platform that integrates advanced computational biology, 3D-modeling, and experimental validation to identify and develop novel antibodies. This proprietary technology aims to precisely target previously undruggable epitopes and validated targets, enhancing therapeutic potential. Their antibody candidates are designed to preserve muscle mass during weight loss, reduce the frequency of dosing, and promote sustained therapeutic effects for improved patient outcomes. The firm focuses on biopharmaceuticals for obesity, cardiometabolic diseases, and hard-to-target cancers, targets patients with unmet needs in weight management and related disorders.